Focus on the implementation of a new round of biomedical "Shanghai plan", promote the acceleration of the whole process of "basic research, incubation and transformation, clinical trials, review and approval, production, promotion and application" and enable the whole chain, and strive to build a world-class biomedical industrial cluster

The Third Plenary Session of the 20th Central Committee of the Communist Party of China made strategic arrangements for improving the mechanism for supporting the development of innovative drugs and medical devices, improving industrial development policies such as biomedicine, and promoting greater opening-up in the medical field. Shanghai will focus on the implementation of a new round of biomedical "Shanghai Plan", further deepening reform as a strong driving force, to promote the "basic research, incubation and transformation, clinical trials, review and approval, production, promotion and application" of the whole process of acceleration and the whole chain of enabling, to build a world-class biomedical industry cluster. We will strive to make greater contributions to promoting the innovative development of biomedicine and improving the health security of all mankind. We will focus on strengthening innovation-driven development, target the frontiers of life sciences, deepen new tracks and new fields, support high-risk and high-value basic research, and build the world's top source of biotechnology innovation. Comply with the new changes in the paradigm of scientific research, promote the accelerated development of artificial intelligence drugs and artificial intelligence medicine, vigorously cultivate more original new drugs, build clinical trial "accelerators", and smooth the "fast track" of transformation and application. We will focus on strengthening the guidance of reform, deepen the coordinated reform and coordinated governance of medical care, medical insurance, and medicine, provide more market space for innovative products, further reduce the comprehensive cost of the industry, and help empower the development of enterprises. Focus on strengthening openness and cooperation, adhere to product development for the global market, clinical trials and international synchronization and homogeneity, support more innovative pharmaceutical companies to deeply integrate into the global innovation chain and industrial chain, and be a good weathervane for expanding high-level opening up.

Promote the deep integration of scientific and technological innovation and industrial innovation, accelerate the construction of a modern pharmaceutical industry system, comprehensively improve the level of supply security, and better meet the health needs of the people

With the implementation of the Action Plan for the High-quality Development of the Pharmaceutical Industry (2023-2025) and the Action Plan for the high-quality Development of the Medical equipment Industry (2023-2025) as the starting point, we will promote the deep integration of scientific and technological innovation and industrial innovation, accelerate the construction of a modern pharmaceutical industry system, comprehensively improve the level of supply security, and better meet the health needs of the vast number of people. We will intensify scientific and technological innovation in the pharmaceutical industry, improve the industry-university-research-medical collaborative research and development system, coordinate efforts to strengthen chains, and foster and develop new quality productivity. Promote the transformation and upgrading of the pharmaceutical industry, adhere to high-end, intelligent and green development, in-depth implementation of the pharmaceutical industry digital intelligent transformation actions, cultivate world-class pharmaceutical enterprises, and build high-end pharmaceutical industry clusters with global influence. We will strengthen the capacity of pharmaceutical production and supply, improve the national pharmaceutical reserve system, and effectively meet public health emergencies and people's drug needs. We will further expand the opening-up and cooperation of the pharmaceutical industry, create a market-oriented, law-based and internationalized first-class business environment, attach equal importance to traditional and Western medicine, promote the inheritance, innovation and development of traditional Chinese medicine and high-quality "going global", and contribute more Chinese solutions to human health.

Strengthen the synergy between scientific and technological innovation and policies and mechanisms in the medical service system, medical insurance payment mechanism, drug supervision, and drug system, and jointly promote the development of new quality productivity in the field of health care

Zeng Yixin pointed out that the Third Plenary session of the 20th Central Committee of the Communist Party of China fully deployed a series of important reform measures to "build a system and mechanism to support comprehensive innovation, deepen the reform of the medical and health system, and improve the development mechanism to support innovative drugs and medical devices." The NHC will fully implement the decision and deployment of the Third Plenary Session of the 20th CPC Central Committee, give full play to the supporting and driving role of scientific and technological innovation in the innovation and development of the pharmaceutical industry, take major scientific and technological projects and policy coordination as the starting point, and encourage application-oriented basic research, cutting-edge technology, clinical research and demonstration promotion. Strive to comprehensively improve the output of major original achievements, key core technology breakthroughs, talent system and research and development platform construction. Focus on the integration of innovation chain and policy chain, strengthen the synergy between scientific and technological innovation and medical service system, medical insurance payment mechanism, drug regulation, drug system and other policies and mechanisms, promote the realization of a policy system supporting the whole innovation chain, jointly promote the development of new quality productivity in the field of health care, and better support the realization of the goal of healthy China and science and technology power.

Marwan Fathalla, Global CEO of the International Drug Information Association, addressed the opening ceremony.

At the opening ceremony, the outstanding progress of industrial upgrading and key areas of future development of industrial technology during the "14th Five-Year Plan" of the pharmaceutical industry were released, and the signing ceremony of the National Excellent Engineer Practice Base (digital technology field) - Joint training of digital engineers in the pharmaceutical industry was held. Representatives of Chinese and foreign pharmaceutical enterprises jointly launched the global cooperation development initiative of the pharmaceutical industry at the scene.

Before the opening ceremony, Chen Jining, Jin Zhuanglong, Zeng Yixin, Gong Zheng and other Chinese and foreign guests visited the typical cases of global cooperation in the pharmaceutical industry.

Municipal leaders Zhu Zhisong, Li Zheng, Liu Duo, President of Shanghai Jiao Tong University Ding Kuiling, Nobel Prize winner Edouard Moser, heads of relevant ministries and commissions attended the opening ceremony. Also attending the opening ceremony were responsible comrades of relevant departments of Shanghai, experts and scholars in the field of medicine at home and abroad, representatives of pharmaceutical enterprises and investment institutions.

From November 16 to 18, 2024 China Pharmaceutical Industry Development Conference and Shanghai International Biomedical Industry Week will be held for the first time in the same period. With the theme of "Create, Share and win-win, join hands in a new quality future", the conference and the Industry Week adopted the form of "1+16+1+N" to hold 1 opening ceremony and main forum, 16 series of special events, 1 typical case exhibition of global cooperation in the pharmaceutical industry and N series of theme activities of the industry week, through the release of results, theme sharing, policy interpretation, roundtable forums, etc. Focusing on the cutting-edge technology innovation of China's pharmaceutical industry and global pharmaceutical cooperation, bringing together the forces of "government, industry, university and research medical funds" to jointly explore new paths in the pharmaceutical industry, promote the cultivation of new quality productivity and future industrial development, and promote the new development of global health.